Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Camrelizumab

Pneumonitis

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Pan S, et al. Case report: Checkpoint inhibitor pneumonitis with positive anti-melanoma differentiation-associated gene 5 antibodies in a patient with lung cancer. Frontiers in Immunology 14: Jan 2024. Available from: URL: https://dx.doi.org/10.3389/fimmu.2023.1309531 Pan S, et al. Case report: Checkpoint inhibitor pneumonitis with positive anti-melanoma differentiation-associated gene 5 antibodies in a patient with lung cancer. Frontiers in Immunology 14: Jan 2024. Available from: URL: https://dx.doi.org/10.3389/fimmu.2023.1309531
Metadaten
Titel
Camrelizumab
Pneumonitis
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-54782-5

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Multiple drugs